Login to Your Account



Bone Regeneration Product Brings in $85M for Osiris

By Catherine Hollingsworth


Monday, May 12, 2008
Osiris Therapeutics Inc. said it plans to sell its Osteocel business to medical device maker NuVasive Inc. for $35 million in an up-front payment at the closing of the deal, and up to $50 million in future milestone payments. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription